TCTMD

AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis

At 3 years, Agent still outshined uncoated balloons. Registry data show rapid uptake of the DCB in the year after its FDA approval.
TCTMD

DCB in STEMI Match DES Through 5 Years: REVELATION

Five-year follow-up from the small, randomized REVELATION trial indicates that rates of clinical events are similar between STEMI patients initially randomized to a drug-coated balloon (DCB) or ...
Healio

DCB may be noninferior to DES in setting of small-vessel CAD, regardless of PCI indication

Please provide your email address to receive an email when new articles are posted on . “PCI is the preferred reperfusion strategy in patients presenting with ACS with latest-generation DES ...
Healio

FDA panel does not recommend approval of DCB for below-the-knee lesions

Please provide your email address to receive an email when new articles are posted on . The FDA’s Circulatory System Devices Panel voted not to recommend approval of a drug-coated balloon to treat ...